Circulating Levels of Inorganic Pyrophosphate Influence the Risk and Clinical Outcomes in Calciphylaxis
Sagar U Nigwekar, Api Chewcharat, Kevin O’Brien, Enock Arthur, Jennifer Howe, Lisa Laurion, Hervé Husson, Houda Bouchouari, Aaron Seto, Yves Sabbagh · 2026
Read Circulating Levels of Inorganic Pyrophosphate Influence the Risk and Clinical Outcomes in Calciphylaxis by Sagar U Nigwekar, Api Chewcharat, Kevin O’Brien, Enock Arthur, Jennifer Howe, Lisa Laurion, Hervé Husson, Houda Bouchouari, Aaron Seto, Yves Sabbagh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571338.txt.
Description
Sagar Nigwekar and co-authors link low levels of a natural calcification blocker to calciphylaxis risk in this 2026 paper. The rare syndrome hardens small vessels and causes painful skin lesions, mostly in kidney failure patients. Survival is often under a year, and no approved therapy exists.
The blocker, inorganic pyrophosphate, stops vessels from calcifying. In a matched study of thirty patients and thirty controls, lower blood levels went with higher disease risk. A seventy-patient cohort tied lower levels to worse severity and higher death rates over twelve weeks. Animal and genetic evidence already suggested the blocker's lack drives vessel hardening. The authors propose raising its levels as a direction for future therapy research.
Catalog record
| CREATOR | Sagar U Nigwekar, Api Chewcharat, Kevin O’Brien, Enock Arthur, Jennifer Howe, Lisa Laurion, Hervé Husson, Houda Bouchouari, Aaron Seto, Yves Sabbagh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |